BioCentury
ARTICLE | Clinical News

SUPG completes Phase III rubitecan study

February 20, 2001 8:00 AM UTC

SuperGen completed enrollment of more than 400 patients in a U.S. Phase III trial comparing its rubitecan oral topoisomerase I inhibitor to 5-FU in patients with pancreatic cancer who were refractory ...